Clinical Trials
-
Principal Investigator:
Frederick Arthur Ehlert, MDThe purpose of this registry is to collect information over time about how Medtronic products are working and/or the outcome of the treatment. The registry will be used to support post-market surveillance/monitoring activities and post-approval studies (e.g., to collect safety and performance information). In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines and patient services/solutions. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies... -
Principal Investigator:
Susheel Kumar Kodali, MDThis is a randomized controlled trial (RCT) that will compare the clinical outcome of MitraClip device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team. In this trial, each subject will be followed until their 10-year visit. Clinical Investigation visits will occur at Screening (for determination of eligibility), Baseline (after confirmation of eligibility), Index Procedure, Discharge, 30 days, 6 months, 1... -
Principal Investigator:
Angelo Bartolo Biviano, MDThe purpose of this study is to assess whether it is safe and effective to stop oral anticoagulation medication (a blood-thinning medication) during prolonged periods of normal heart rhythm in participants with infrequent episodes of atrial fibrillation (AF). Atrial fibrillation (AF) is the most common abnormal heart rhythm and is associated with an increased risk of stroke, heart failure, and death. -
Principal Investigator:
Ajay J. Kirtane, MDWe are doing this study to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This is an FDA approved device. Involvement in the study is expected to last approximately 60 months. Patients will be asked to collect blood pressure (BP) at home, to help us understand how ultrasound renal denervation impacts their blood pressure over time. Patients will receive home BP monitor device for the entire duration of the study and will be trained how to use it. -
Principal Investigator:
Jennifer H Haythe, MDWe are doing this study to test the use of a drug called bromocriptine for women with a condition called Peripartum cardiomyopathy (PPCM). The study will look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill. -
Principal Investigator:
Jennifer H Haythe, MDWe are doing this study to test the use of a drug called bromocriptine for women with a condition called Peripartum cardiomyopathy (PPCM). The study will look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill. -
Principal Investigator:
Hirad Yarmohammadi, MDYou may want to join this study because your heart condition may respond to a device-based therapy called cardiac modulation therapy called the OPTIMIZER System. The OPTIMIZER INTEGRA CCM-D System, also known as a Cardiac Contractility Modulation Defibrillator, is an investigational device system that combines CCM therapy and ICD therapy into one device. Investigational means that the study device is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). If you choose to be part of this research, you will be asked to provide blood and will undergo... -
Principal Investigator:
Keith Diaz, PhDU.S. Adults spend on average 11 to 12 hours a day sitting. Daily sedentary behavior is strongly associated with the risk of heart disease. The purpose of the BREAK II research study is to answer two questions: (1) How frequently should periods of prolonged sedentary time be interrupted? and (2) What is the appropriate duration or length of time of these breaks in sedentary time? If you are 18 years old or older and have no history of chronic diseases, and no physical disability preventing ability to walk and a non-smoker, you may be eligible for this study. Participants will receive up to $... -
Principal Investigator:
Gabriel Tal Sayer, MDThis is a prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Repair System in patients with heart failure and reduced ejection fraction (HFrEF). -
Principal Investigator:
Dor Lotan, MDThe main purpose of the study is to evaluate if treatment with CardioRX will prevent pericarditis recurrences after the therapy with IL-1 blocker (medication to reduce inflammation) has been stopped. You are being asked to join the study because you have recurrent pericarditis. Pericarditis is inflammation of the percardium (double layer sac that surrounds the heart). The pericardium allows your heart to move freely with each heartbeat. Recurrent pericarditis is an episode of pericarditis that occurs after a symptom-free period of more than 4 weeks after the last episode. CardioRX is the...